GSE236055

Colonic mucosal gene expression profile associated with neoplastic progression in longstanding ulcerative colitis

Whole-study status Not suitable

Dataset does not meet the current suitability threshold.

Whole-study downloads — these do not apply your sample requirements.

Selected cohort requirements

Samples meeting selected requirements: 0 cases / 0 controls

View matching samples

143 case / 0 control samples elsewhere in the study have incomplete or conflicting evidence; they are not included above

Patient pairs verified in indexed sample metadata: 0

A case/control comparison meeting these requirements is not confirmed.

Counts describe samples, not independent patients. Pair verification uses explicit subject identifiers in indexed sample metadata. Zero verified pairs does not establish that the study is unpaired; reported matched-normal design alone is insufficient.

Summary

Introduction: Many gene expression studies of colitis-associated colorectal cancer (CA-CRC) in patients with ulcerative colitis (UC) have focused on identification of molecular drivers of progression of UC to CA- CRC. However, they have primarily studied cancerous mucosal biopsies, an approach which primarily may identify the characteristics of the established cancer mucosa and not the early molecular events driving the progression. Long-standing mucosal inflammation is suspected to be one of the main drivers of CA-CRC. Still, not all patients with UC progress and develop cancer. We hypothesise that patients with UC, who have progressed to neoplasia (progressors), have a different molecular profile of inflammation than non-progressors. Methods: We performed transcriptome profiling on 143 mucosal biopsies from non-neoplastic colonic segments of 14 UC progressors and 30 UC non-progressors. In addition, we performed profiling of lymphocyte infiltration to the mucosa of biopsies taken adjacent to biopsies used for transcriptomic analysis. Results: We found a characteristic gene expression profile for inflamed mucosa of UC progressors, which primarily is associated with progression of UC to dysplasia or cancer as opposed to long duration of disease. The gene expression profile suggests that the inflamed tissue of UC progressors is negatively enriched for biological processes such as adaptive immune responses and complement system activity and positively enriched for biological processes related to detoxification. Moreover, we found that the microenvironment in the inflamed mucosa of progressors differs from non-progressors by having fewer infiltrating B cells and less lymphoid aggregates. Conclusions: We found that inflammation of UC patients, who have progressed to dysplasia or cancer, has a different gene expression profile than that of UC non-progressors. Importantly, this profile was primarily associated with progression of disease as opposed to duration of disease. The inflamed mucosa of UC progressors may have lower levels of lymphoid organ-initiating and immune cell- attracting signals and fewer immune cells infiltrating the mucosa. Consequently, progressors may lack the ability to mount sufficient adaptive immune responses necessary to counteract driving forces of malignant transformation in UC.

Overall design

Patients from the prospective Lovisenberg Diakonale Hospital (LDS) and the prospective CA-CRC cohort from Akershus University Hospital (Ahus) were included in the study. In short, this study consists of patients with UC, who are at high risk for CA-CRC e.g., presenting with extension of inflammation proximal to splenic flexure (pancolitis) and at least eight years of disease duration from diagnosis of UC. Non-targeted biopsies were taken from each segment of the colon (ascending, transverse, descending and sigmoid colon as well as rectum). A biopsy was also taken within 2-4 cm of any lesions. Biopsies were preserved in liquid nitrogen. The analysis of gene expression included 14 progressors (five with CA-CRC, two with HGD, seven with LGD) and 30 non-progressors. In total 143 colon biopsies (49 progressor samples and 94 non-progressor samples) were analyzed covering histological non-neoplastic, non-inflamed as well as non-neoplastic, inflamed tissue from right and left colon and rectum. Samples were assigned to groups of non-inflamed and inflamed samples from non-progressor and progressor patients, respectively, resulting in four main sample groups. In addition, inflamed samples were assigned to chronic inflammation and chronic active inflammationfor non-progressors and progressors, respectively, resulting in four inflammation subgroups. All samples were located distant from lesions in the colon with dysplasia or cancer.

Source Evidence

4 sources
Source Contribution Status
GEO

Original dataset metadata, sample metadata, source links, and GEO data availability flags.

Sample records
143 GSM samples
Primary source
recount3

Planned trusted source for processed count availability.

No match found
Expression Atlas

Planned source for curated expression experiment links.

No match found
PubMed

Primary GEO citations and related PubMed articles that mention this dataset.

1 linked publication 1 DOI

Primary publication

  1. Colonic Mucosal Gene Expression Profile in Patients with Neoplastic Progression in Longstanding Ulcerative Colitis. Clinical and experimental gastroenterology, 2025
Available

Metadata Quality Components

Analysis Readiness

Not ready
55% DE readiness

Contrast completeness

10/25 pts

Only one side of the contrast is present; downstream DE needs both groups.

Minimum group size

0/20 pts

Minimum group size cannot be evaluated until a complete contrast exists.

Processed data availability

20/20 pts

Processed data is marked available in the GEO index.

Sample decision clarity

15/15 pts

All samples are assigned to a case or control group.

Blocking warnings

0/10 pts

Critical warnings must be resolved before downstream analysis.

Metadata normalization

10/10 pts

Metadata quality is high enough to support downstream handoff.

Blockers

  • No complete case/control contrast is available.
  • Critical dataset warnings must be resolved.

Next Steps

  • Resolve critical warnings before downstream analysis.

Analysis Preparation Checklist

4/6 ready

Group labels reviewed

Blocked

No complete case/control grouping exists yet.

Review the sample grouping table and assign both case and control groups.

Minimum sample count met

Blocked

At least one group has fewer than 2 samples.

Choose a larger dataset or merge only scientifically valid groups.

Processed counts available

Ready

Processed data availability is marked true in the GEO index.

Verify that downloaded processed files contain usable count or expression identifiers.

Ambiguous samples handled

Ready

No review-needed or unassigned samples are present in the proposed grouping.

Review the grouping table for biologically meaningful differences that the automated checks may not detect.

Exclusion decisions recorded

Ready

No hard-excluded samples were detected by the current rules.

Record any manual exclusions in the downstream analysis notes.

Source traceability preserved

Ready

The dataset and sample accessions can be traced back to GEO.

Keep GEO accessions with exported metadata.

Bioinformatician Review

Bioinformatician review required

Ask a bioinformatician to review grouping, count availability, exclusions, and design before DE.

Analysis readiness has blockers that must be resolved before DE.

Analysis preparation checklist contains blocked items.

No complete case/control or treatment/control contrast is available.

At least one comparison group has fewer than two samples.

Critical dataset warnings are present.

Assay context may require expert handling before DESeq2-style analysis.

Study design is model-system or unclear and should be reviewed before analysis.

Why This Is Ranked Here

Tumor vs normal
Not suitable Dataset does not meet the current suitability threshold.

Applied Review Decisions

No active review decisions affect this ranking.

Derived Classifications

  • Assay differs from search intent Microarray Search intent expects bulk RNA-seq. Assay came from Normalization rules.
  • Disease context Amyotrophic lateral sclerosis, colorectal cancer, inflammatory bowel disease, ulcerative colitis Disease context came from Normalization rules.
  • Likely case group Inflamed tissue 143 samples
  • Likely control group No control group detected 0 samples

Intent Interpretation

  • Downgrade or exclusion reason Comparison: Unclear study design. Specimen: Tissue. Comparison suitability: 0%. Derived from current-intent ranking reasons.

Ranking Facts

Supporting evidence

  • Interpreted disease metadata: Colorectal cancer, Inflammatory bowel disease, Ulcerative colitis.
  • Processed data is available for downstream review.
  • External evidence: PubMed links 1 publication; 1 DOI available: PMID 40989939.
  • Publication context: Colonic Mucosal Gene Expression Profile in Patients with Neoplastic Progression in Longstanding Ulcerative Colitis.. Clinical and experimental gastroenterology, 2025. PMID 40989939. DOI 10.2147/CEG.S528854.

Cautions

  • Comparison: Unclear study design. Specimen: Tissue. Comparison suitability: 0%.
  • Downgraded for tissue search because study design or specimen source is unclear.
  • Downgraded assay: microarray cohorts are separated from the RNA-seq intent.
  • Unclear study design downgraded for patient tissue tumor-vs-normal search intent.
  • Missing or unclear metadata. Unclear study design downgraded for patient tissue tumor-vs-normal search intent.
  • Overall score capped because comparison suitability is weak for the selected search intent.
  • Missing or unclear metadata. Comparison - Unclear study design. Specimen - Tissue. Comparison suitability: 0%.
  • Missing or unclear metadata. Downgraded for tissue search because study design or specimen source is unclear.
  • Comparison suitability score is below the Phase 1 recommended threshold.

Dataset Warnings

Normalized Fields

366 fields

Sample Group Preview

showing 50 of 143 preview rows
Show Hide
Study totals: Case 143 | Control 0 | Unassigned 0 | Excluded 0 | Ambiguous 0 showing 50 of 143 preview rows
Group Role Accession Title Source / characteristics Reason
Inflamed tissue Case GSM7517415 NP, Rectum, 257236323159_1_2 Rectum Disease state: UC; Progressor_status: NP; Inflammation_status: None; Gender: M; Age_at_diagnosis: 27; Age_at_inclusion: 67; Disease_duration_yr: 39.95; Salazopyrine: 1; x5_asa: 0; Azathioprine_metotrexate: 0; Infliximab: 0; Adalimumab: 0; Vedolizumab: 0; Other_medications: 1; Tissue: Rectum; Patient_id: AS061 Case marker detected.
Inflamed tissue Case GSM7517416 NP, Ascending, 257236323159_1_3 Ascending Disease state: UC; Progressor_status: NP; Inflammation_status: None; Gender: M; Age_at_diagnosis: 27; Age_at_inclusion: 67; Disease_duration_yr: 39.95; Salazopyrine: 1; x5_asa: 0; Azathioprine_metotrexate: 0; Infliximab: 0; Adalimumab: 0; Vedolizumab: 0; Other_medications: 1; Tissue: Ascending; Patient_id: AS062 Case marker detected.
Inflamed tissue Case GSM7517417 NP, Descending, 257236323159_1_4 Descending Disease state: UC; Progressor_status: NP; Inflammation_status: None; Gender: M; Age_at_diagnosis: 27; Age_at_inclusion: 67; Disease_duration_yr: 39.95; Salazopyrine: 1; x5_asa: 0; Azathioprine_metotrexate: 0; Infliximab: 0; Adalimumab: 0; Vedolizumab: 0; Other_medications: 1; Tissue: Descending; Patient_id: AS062 Case marker detected.
Inflamed tissue Case GSM7517418 NP, Rectum, 257236323159_2_1 Rectum Disease state: UC; Progressor_status: NP; Inflammation_status: None; Gender: M; Age_at_diagnosis: 27; Age_at_inclusion: 67; Disease_duration_yr: 39.95; Salazopyrine: 1; x5_asa: 0; Azathioprine_metotrexate: 0; Infliximab: 0; Adalimumab: 0; Vedolizumab: 0; Other_medications: 1; Tissue: Rectum; Patient_id: AS062 Case marker detected.
Inflamed tissue Case GSM7517419 NP, Ascending, 257236323159_2_2 Ascending Disease state: UC; Progressor_status: NP; Inflammation_status: None; Gender: M; Age_at_diagnosis: 27; Age_at_inclusion: 64; Disease_duration_yr: 37.18; Salazopyrine: 1; x5_asa: 0; Azathioprine_metotrexate: 0; Infliximab: 0; Adalimumab: 0; Vedolizumab: 0; Other_medications: 1; Tissue: Ascending; Patient_id: AS066 Case marker detected.
Inflamed tissue Case GSM7517420 NP, Descending, 257236323159_2_3 Descending Disease state: UC; Progressor_status: NP; Inflammation_status: None; Gender: M; Age_at_diagnosis: 27; Age_at_inclusion: 64; Disease_duration_yr: 37.18; Salazopyrine: 1; x5_asa: 0; Azathioprine_metotrexate: 0; Infliximab: 0; Adalimumab: 0; Vedolizumab: 0; Other_medications: 1; Tissue: Descending; Patient_id: AS066 Case marker detected.
Inflamed tissue Case GSM7517421 NP, Rectum, 257236323159_2_4 Rectum Disease state: UC; Progressor_status: NP; Inflammation_status: None; Gender: M; Age_at_diagnosis: 27; Age_at_inclusion: 64; Disease_duration_yr: 37.18; Salazopyrine: 1; x5_asa: 0; Azathioprine_metotrexate: 0; Infliximab: 0; Adalimumab: 0; Vedolizumab: 0; Other_medications: 1; Tissue: Rectum; Patient_id: AS066 Case marker detected.
Inflamed tissue Case GSM7517422 NP, Rectum, 257236323160_1_1 Rectum Disease state: UC; Progressor_status: NP; Inflammation_status: None; Gender: M; Age_at_diagnosis: 41; Age_at_inclusion: 54; Disease_duration_yr: 12.49; Salazopyrine: 0; x5_asa: 0; Azathioprine_metotrexate: 1; Infliximab: 0; Adalimumab: 0; Vedolizumab: 0; Other_medications: 1; Tissue: Rectum; Patient_id: AS050 Case marker detected.
Inflamed tissue Case GSM7517423 NP, Ascending, 257236323160_1_4 Ascending Disease state: UC; Progressor_status: NP; Inflammation_status: None; Gender: M; Age_at_diagnosis: 41; Age_at_inclusion: 54; Disease_duration_yr: 12.49; Salazopyrine: 0; x5_asa: 0; Azathioprine_metotrexate: 1; Infliximab: 0; Adalimumab: 0; Vedolizumab: 0; Other_medications: 1; Tissue: Ascending; Patient_id: AS058 Case marker detected.
Inflamed tissue Case GSM7517424 NP, Descending, 257236323160_2_1 Descending Disease state: UC; Progressor_status: NP; Inflammation_status: None; Gender: M; Age_at_diagnosis: 41; Age_at_inclusion: 54; Disease_duration_yr: 12.49; Salazopyrine: 0; x5_asa: 0; Azathioprine_metotrexate: 1; Infliximab: 0; Adalimumab: 0; Vedolizumab: 0; Other_medications: 1; Tissue: Descending; Patient_id: AS058 Case marker detected.
Inflamed tissue Case GSM7517425 NP, Rectum, 257236323160_2_2 Rectum Disease state: UC; Progressor_status: NP; Inflammation_status: None; Gender: M; Age_at_diagnosis: 16; Age_at_inclusion: 55; Disease_duration_yr: 38.25; Salazopyrine: 1; x5_asa: 0; Azathioprine_metotrexate: 0; Infliximab: 0; Adalimumab: 0; Vedolizumab: 0; Other_medications: 1; Tissue: Rectum; Patient_id: AS058 Case marker detected.
Inflamed tissue Case GSM7517426 NP, Ascending, 257236323160_2_3 Ascending Disease state: UC; Progressor_status: NP; Inflammation_status: None; Gender: M; Age_at_diagnosis: 16; Age_at_inclusion: 55; Disease_duration_yr: 38.25; Salazopyrine: 1; x5_asa: 0; Azathioprine_metotrexate: 0; Infliximab: 0; Adalimumab: 0; Vedolizumab: 0; Other_medications: 1; Tissue: Ascending; Patient_id: AS061 Case marker detected.
Inflamed tissue Case GSM7517427 NP, Descending, 257236323160_2_4 Descending Disease state: UC; Progressor_status: NP; Inflammation_status: None; Gender: M; Age_at_diagnosis: 16; Age_at_inclusion: 55; Disease_duration_yr: 38.25; Salazopyrine: 1; x5_asa: 0; Azathioprine_metotrexate: 0; Infliximab: 0; Adalimumab: 0; Vedolizumab: 0; Other_medications: 1; Tissue: Descending; Patient_id: AS061 Case marker detected.
Inflamed tissue Case GSM7517428 NP, Rectum, 257236323161_1_1 Rectum Disease state: UC; Progressor_status: NP; Inflammation_status: None; Gender: M; Age_at_diagnosis: 16; Age_at_inclusion: 55; Disease_duration_yr: 38.25; Salazopyrine: 1; x5_asa: 0; Azathioprine_metotrexate: 0; Infliximab: 0; Adalimumab: 0; Vedolizumab: 0; Other_medications: 1; Tissue: Rectum; Patient_id: AS044 Case marker detected.
Inflamed tissue Case GSM7517429 P, Transverse, 257236323161_1_3 Transverse Disease state: UC; Progressor_status: P; Inflammation_status: None; Gender: M; Age_at_diagnosis: 16; Age_at_inclusion: 55; Disease_duration_yr: 38.25; Salazopyrine: 1; x5_asa: 0; Azathioprine_metotrexate: 0; Infliximab: 0; Adalimumab: 0; Vedolizumab: 0; Other_medications: 1; Tissue: Transverse; Patient_id: AS048 Case marker detected.
Inflamed tissue Case GSM7517430 NP, Ascending, 257236323161_2_3 Ascending Disease state: UC; Progressor_status: NP; Inflammation_status: None; Gender: M; Age_at_diagnosis: 16; Age_at_inclusion: 55; Disease_duration_yr: 38.25; Salazopyrine: 1; x5_asa: 0; Azathioprine_metotrexate: 0; Infliximab: 0; Adalimumab: 0; Vedolizumab: 0; Other_medications: 1; Tissue: Ascending; Patient_id: AS050 Case marker detected.
Inflamed tissue Case GSM7517431 NP, Descending, 257236323161_2_4 Descending Disease state: UC; Progressor_status: NP; Inflammation_status: None; Gender: M; Age_at_diagnosis: 16; Age_at_inclusion: 55; Disease_duration_yr: 38.25; Salazopyrine: 1; x5_asa: 0; Azathioprine_metotrexate: 0; Infliximab: 0; Adalimumab: 0; Vedolizumab: 0; Other_medications: 1; Tissue: Descending; Patient_id: AS050 Case marker detected.
Inflamed tissue Case GSM7517432 NP, Ascending, 257236324305_1_1 Ascending Disease state: UC; Progressor_status: NP; Inflammation_status: None; Gender: M; Age_at_diagnosis: 17; Age_at_inclusion: 70; Disease_duration_yr: 53.27; Salazopyrine: 0; x5_asa: 1; Azathioprine_metotrexate: 0; Infliximab: 0; Adalimumab: 0; Vedolizumab: 0; Other_medications: 1; Tissue: Ascending; Patient_id: AS027 Case marker detected.
Inflamed tissue Case GSM7517433 NP, Descending, 257236324305_1_2 Descending Disease state: UC; Progressor_status: NP; Inflammation_status: Chronic; Gender: M; Age_at_diagnosis: 17; Age_at_inclusion: 70; Disease_duration_yr: 53.27; Salazopyrine: 0; x5_asa: 1; Azathioprine_metotrexate: 0; Infliximab: 0; Adalimumab: 0; Vedolizumab: 0; Other_medications: 1; Tissue: Descending; Patient_id: AS027 Case marker detected.
Inflamed tissue Case GSM7517434 NP, Rectum, 257236324305_1_3 Rectum Disease state: UC; Progressor_status: NP; Inflammation_status: None; Gender: M; Age_at_diagnosis: 17; Age_at_inclusion: 70; Disease_duration_yr: 53.27; Salazopyrine: 0; x5_asa: 1; Azathioprine_metotrexate: 0; Infliximab: 0; Adalimumab: 0; Vedolizumab: 0; Other_medications: 1; Tissue: Rectum; Patient_id: AS027 Case marker detected.
Inflamed tissue Case GSM7517435 NP, Ascending, 257236324305_1_4 Ascending Disease state: UC; Progressor_status: NP; Inflammation_status: None; Gender: M; Age_at_diagnosis: 17; Age_at_inclusion: 70; Disease_duration_yr: 53.27; Salazopyrine: 0; x5_asa: 1; Azathioprine_metotrexate: 0; Infliximab: 0; Adalimumab: 0; Vedolizumab: 0; Other_medications: 1; Tissue: Ascending; Patient_id: AS036 Case marker detected.
Inflamed tissue Case GSM7517436 NP, Descending, 257236324305_2_1 Descending Disease state: UC; Progressor_status: NP; Inflammation_status: None; Gender: F; Age_at_diagnosis: 46; Age_at_inclusion: 62; Disease_duration_yr: 16.29; Salazopyrine: 0; x5_asa: 1; Azathioprine_metotrexate: 0; Infliximab: 0; Adalimumab: 0; Vedolizumab: 0; Other_medications: 0; Tissue: Descending; Patient_id: AS036 Case marker detected.
Inflamed tissue Case GSM7517437 NP, Rectum, 257236324305_2_2 Rectum Disease state: UC; Progressor_status: NP; Inflammation_status: None; Gender: F; Age_at_diagnosis: 46; Age_at_inclusion: 62; Disease_duration_yr: 16.29; Salazopyrine: 0; x5_asa: 1; Azathioprine_metotrexate: 0; Infliximab: 0; Adalimumab: 0; Vedolizumab: 0; Other_medications: 0; Tissue: Rectum; Patient_id: AS036 Case marker detected.
Inflamed tissue Case GSM7517438 NP, Ascending, 257236324305_2_3 Ascending Disease state: UC; Progressor_status: NP; Inflammation_status: None; Gender: F; Age_at_diagnosis: 46; Age_at_inclusion: 62; Disease_duration_yr: 16.29; Salazopyrine: 0; x5_asa: 1; Azathioprine_metotrexate: 0; Infliximab: 0; Adalimumab: 0; Vedolizumab: 0; Other_medications: 0; Tissue: Ascending; Patient_id: AS038 Case marker detected.
Inflamed tissue Case GSM7517439 NP, Descending, 257236324305_2_4 Descending Disease state: UC; Progressor_status: NP; Inflammation_status: Chronic; Gender: M; Age_at_diagnosis: 17; Age_at_inclusion: 30; Disease_duration_yr: 13.42; Salazopyrine: 0; x5_asa: 1; Azathioprine_metotrexate: 0; Infliximab: 0; Adalimumab: 0; Vedolizumab: 0; Other_medications: 0; Tissue: Descending; Patient_id: AS038 Case marker detected.
Inflamed tissue Case GSM7517440 NP, Rectum, 257236324320_1_1 Rectum Disease state: UC; Progressor_status: NP; Inflammation_status: Chronic_active; Gender: M; Age_at_diagnosis: 35; Age_at_inclusion: 44; Disease_duration_yr: 8.69; Salazopyrine: 0; x5_asa: 1; Azathioprine_metotrexate: 0; Infliximab: 0; Adalimumab: 0; Vedolizumab: 0; Other_medications: 0; Tissue: Rectum; Patient_id: AS069 Case marker detected.
Inflamed tissue Case GSM7517441 NP, Ascending, 257236324320_1_2 Ascending Disease state: UC; Progressor_status: NP; Inflammation_status: Chronic_active; Gender: M; Age_at_diagnosis: 35; Age_at_inclusion: 44; Disease_duration_yr: 8.69; Salazopyrine: 0; x5_asa: 1; Azathioprine_metotrexate: 0; Infliximab: 0; Adalimumab: 0; Vedolizumab: 0; Other_medications: 0; Tissue: Ascending; Patient_id: AS081 Case marker detected.
Inflamed tissue Case GSM7517442 NP, Descending, 257236324320_1_3 Descending Disease state: UC; Progressor_status: NP; Inflammation_status: None; Gender: M; Age_at_diagnosis: 35; Age_at_inclusion: 44; Disease_duration_yr: 8.69; Salazopyrine: 0; x5_asa: 1; Azathioprine_metotrexate: 0; Infliximab: 0; Adalimumab: 0; Vedolizumab: 0; Other_medications: 0; Tissue: Descending; Patient_id: AS081 Case marker detected.
Inflamed tissue Case GSM7517443 NP, Rectum, 257236324320_1_4 Rectum Disease state: UC; Progressor_status: NP; Inflammation_status: None; Gender: F; Age_at_diagnosis: 27; Age_at_inclusion: 46; Disease_duration_yr: 19.59; Salazopyrine: 0; x5_asa: 1; Azathioprine_metotrexate: 1; Infliximab: 1; Adalimumab: 0; Vedolizumab: 0; Other_medications: 0; Tissue: Rectum; Patient_id: AS081 Case marker detected.
Inflamed tissue Case GSM7517444 NP, Ascending, 257236324320_2_1 Ascending Disease state: UC; Progressor_status: NP; Inflammation_status: None; Gender: F; Age_at_diagnosis: 27; Age_at_inclusion: 46; Disease_duration_yr: 19.59; Salazopyrine: 0; x5_asa: 1; Azathioprine_metotrexate: 1; Infliximab: 1; Adalimumab: 0; Vedolizumab: 0; Other_medications: 0; Tissue: Ascending; Patient_id: AS082 Case marker detected.
Inflamed tissue Case GSM7517445 NP, Descending, 257236324320_2_2 Descending Disease state: UC; Progressor_status: NP; Inflammation_status: None; Gender: F; Age_at_diagnosis: 27; Age_at_inclusion: 46; Disease_duration_yr: 19.59; Salazopyrine: 0; x5_asa: 1; Azathioprine_metotrexate: 1; Infliximab: 1; Adalimumab: 0; Vedolizumab: 0; Other_medications: 0; Tissue: Descending; Patient_id: AS082 Case marker detected.
Inflamed tissue Case GSM7517446 NP, Rectum, 257236324320_2_3 Rectum Disease state: UC; Progressor_status: NP; Inflammation_status: Chronic_active; Gender: F; Age_at_diagnosis: 34; Age_at_inclusion: 42; Disease_duration_yr: 8.44; Salazopyrine: 0; x5_asa: 0; Azathioprine_metotrexate: 0; Infliximab: 0; Adalimumab: 0; Vedolizumab: 0; Other_medications: 0; Tissue: Rectum; Patient_id: AS082 Case marker detected.
Inflamed tissue Case GSM7517447 NP, Ascending, 257236324320_2_4 Ascending Disease state: UC; Progressor_status: NP; Inflammation_status: Chronic; Gender: F; Age_at_diagnosis: 34; Age_at_inclusion: 42; Disease_duration_yr: 8.44; Salazopyrine: 0; x5_asa: 0; Azathioprine_metotrexate: 0; Infliximab: 0; Adalimumab: 0; Vedolizumab: 0; Other_medications: 0; Tissue: Ascending; Patient_id: AS086 Case marker detected.
Inflamed tissue Case GSM7517448 NP, Descending, 257236324321_1_1 Descending Disease state: UC; Progressor_status: NP; Inflammation_status: None; Gender: F; Age_at_diagnosis: 34; Age_at_inclusion: 42; Disease_duration_yr: 8.44; Salazopyrine: 0; x5_asa: 0; Azathioprine_metotrexate: 0; Infliximab: 0; Adalimumab: 0; Vedolizumab: 0; Other_medications: 0; Tissue: Descending; Patient_id: AS086 Case marker detected.
Inflamed tissue Case GSM7517449 NP, Rectum, 257236324321_1_2 Rectum Disease state: UC; Progressor_status: NP; Inflammation_status: None; Gender: F; Age_at_diagnosis: 34; Age_at_inclusion: 42; Disease_duration_yr: 8.44; Salazopyrine: 0; x5_asa: 0; Azathioprine_metotrexate: 0; Infliximab: 0; Adalimumab: 0; Vedolizumab: 0; Other_medications: 0; Tissue: Rectum; Patient_id: AS086 Case marker detected.
Inflamed tissue Case GSM7517450 NP, Ascending, 257236324321_1_3 Ascending Disease state: UC; Progressor_status: NP; Inflammation_status: None; Gender: M; Age_at_diagnosis: 43; Age_at_inclusion: 65; Disease_duration_yr: 21.65; Salazopyrine: 0; x5_asa: 1; Azathioprine_metotrexate: 0; Infliximab: 0; Adalimumab: 0; Vedolizumab: 0; Other_medications: 0; Tissue: Ascending; Patient_id: AS095 Case marker detected.
Inflamed tissue Case GSM7517451 NP, Sigmoid, 257236324321_1_4 Sigmoid Disease state: UC; Progressor_status: NP; Inflammation_status: None; Gender: M; Age_at_diagnosis: 43; Age_at_inclusion: 65; Disease_duration_yr: 21.65; Salazopyrine: 0; x5_asa: 1; Azathioprine_metotrexate: 0; Infliximab: 0; Adalimumab: 0; Vedolizumab: 0; Other_medications: 0; Tissue: Sigmoid; Patient_id: AS095 Case marker detected.
Inflamed tissue Case GSM7517452 NP, Rectum, 257236324321_2_1 Rectum Disease state: UC; Progressor_status: NP; Inflammation_status: None; Gender: M; Age_at_diagnosis: 43; Age_at_inclusion: 65; Disease_duration_yr: 21.65; Salazopyrine: 0; x5_asa: 1; Azathioprine_metotrexate: 0; Infliximab: 0; Adalimumab: 0; Vedolizumab: 0; Other_medications: 0; Tissue: Rectum; Patient_id: AS095 Case marker detected.
Inflamed tissue Case GSM7517453 NP, Ascending, 257236324321_2_2 Ascending Disease state: UC; Progressor_status: NP; Inflammation_status: None; Gender: M; Age_at_diagnosis: 50; Age_at_inclusion: 61; Disease_duration_yr: 10.69; Salazopyrine: 0; x5_asa: 1; Azathioprine_metotrexate: 0; Infliximab: 0; Adalimumab: 0; Vedolizumab: 0; Other_medications: 0; Tissue: Ascending; Patient_id: AS096 Case marker detected.
Inflamed tissue Case GSM7517454 NP, Descending, 257236324321_2_3 Descending Disease state: UC; Progressor_status: NP; Inflammation_status: None; Gender: M; Age_at_diagnosis: 50; Age_at_inclusion: 61; Disease_duration_yr: 10.69; Salazopyrine: 0; x5_asa: 1; Azathioprine_metotrexate: 0; Infliximab: 0; Adalimumab: 0; Vedolizumab: 0; Other_medications: 0; Tissue: Descending; Patient_id: AS096 Case marker detected.
Inflamed tissue Case GSM7517455 NP, Rectum, 257236324321_2_4 Rectum Disease state: UC; Progressor_status: NP; Inflammation_status: None; Gender: M; Age_at_diagnosis: 50; Age_at_inclusion: 61; Disease_duration_yr: 10.69; Salazopyrine: 0; x5_asa: 1; Azathioprine_metotrexate: 0; Infliximab: 0; Adalimumab: 0; Vedolizumab: 0; Other_medications: 0; Tissue: Rectum; Patient_id: AS096 Case marker detected.
Inflamed tissue Case GSM7517456 NP, Ascending, 257236324322_1_1 Ascending Disease state: UC; Progressor_status: NP; Inflammation_status: None; Gender: M; Age_at_diagnosis: 38; Age_at_inclusion: 56; Disease_duration_yr: 17.71; Salazopyrine: 0; x5_asa: 1; Azathioprine_metotrexate: 1; Infliximab: 0; Adalimumab: 0; Vedolizumab: 0; Other_medications: 0; Tissue: Ascending; Patient_id: AS067 Case marker detected.
Inflamed tissue Case GSM7517457 NP, Descending, 257236324322_1_2 Descending Disease state: UC; Progressor_status: NP; Inflammation_status: None; Gender: M; Age_at_diagnosis: 38; Age_at_inclusion: 56; Disease_duration_yr: 17.71; Salazopyrine: 0; x5_asa: 1; Azathioprine_metotrexate: 1; Infliximab: 0; Adalimumab: 0; Vedolizumab: 0; Other_medications: 0; Tissue: Descending; Patient_id: AS067 Case marker detected.
Inflamed tissue Case GSM7517458 NP, Rectum, 257236324322_1_3 Rectum Disease state: UC; Progressor_status: NP; Inflammation_status: None; Gender: M; Age_at_diagnosis: 38; Age_at_inclusion: 56; Disease_duration_yr: 17.71; Salazopyrine: 0; x5_asa: 1; Azathioprine_metotrexate: 1; Infliximab: 0; Adalimumab: 0; Vedolizumab: 0; Other_medications: 0; Tissue: Rectum; Patient_id: AS067 Case marker detected.
Inflamed tissue Case GSM7517459 NP, Ascending, 257236324322_1_4 Ascending Disease state: UC; Progressor_status: NP; Inflammation_status: None; Gender: F; Age_at_diagnosis: 50; Age_at_inclusion: 61; Disease_duration_yr: 11.14; Salazopyrine: 0; x5_asa: 0; Azathioprine_metotrexate: 0; Infliximab: 0; Adalimumab: 1; Vedolizumab: 0; Other_medications: 1; Tissue: Ascending; Patient_id: AS068 Case marker detected.
Inflamed tissue Case GSM7517460 NP, Descending, 257236324322_2_1 Descending Disease state: UC; Progressor_status: NP; Inflammation_status: None; Gender: F; Age_at_diagnosis: 50; Age_at_inclusion: 61; Disease_duration_yr: 11.14; Salazopyrine: 0; x5_asa: 0; Azathioprine_metotrexate: 0; Infliximab: 0; Adalimumab: 1; Vedolizumab: 0; Other_medications: 1; Tissue: Descending; Patient_id: AS068 Case marker detected.
Inflamed tissue Case GSM7517461 NP, Rectum, 257236324322_2_2 Rectum Disease state: UC; Progressor_status: NP; Inflammation_status: None; Gender: F; Age_at_diagnosis: 50; Age_at_inclusion: 61; Disease_duration_yr: 11.14; Salazopyrine: 0; x5_asa: 0; Azathioprine_metotrexate: 0; Infliximab: 0; Adalimumab: 1; Vedolizumab: 0; Other_medications: 1; Tissue: Rectum; Patient_id: AS068 Case marker detected.
Inflamed tissue Case GSM7517462 NP, Ascending, 257236324322_2_3 Ascending Disease state: UC; Progressor_status: NP; Inflammation_status: None; Gender: F; Age_at_diagnosis: 33; Age_at_inclusion: 43; Disease_duration_yr: 10.55; Salazopyrine: 0; x5_asa: 1; Azathioprine_metotrexate: 0; Infliximab: 0; Adalimumab: 0; Vedolizumab: 0; Other_medications: 0; Tissue: Ascending; Patient_id: AS069 Case marker detected.
Inflamed tissue Case GSM7517463 NP, Descending, 257236324322_2_4 Descending Disease state: UC; Progressor_status: NP; Inflammation_status: None; Gender: F; Age_at_diagnosis: 33; Age_at_inclusion: 43; Disease_duration_yr: 10.55; Salazopyrine: 0; x5_asa: 1; Azathioprine_metotrexate: 0; Infliximab: 0; Adalimumab: 0; Vedolizumab: 0; Other_medications: 0; Tissue: Descending; Patient_id: AS069 Case marker detected.
Inflamed tissue Case GSM7517464 P, Rectum, 257236324323_1_1 Rectum Disease state: UC; Progressor_status: P; Inflammation_status: None; Gender: F; Age_at_diagnosis: 33; Age_at_inclusion: 43; Disease_duration_yr: 10.55; Salazopyrine: 0; x5_asa: 1; Azathioprine_metotrexate: 0; Infliximab: 0; Adalimumab: 0; Vedolizumab: 0; Other_medications: 0; Tissue: Rectum; Patient_id: AS041 Case marker detected.
93 additional case samples are hidden from this preview.

Use as Discovery Cohort

External Validation Finder

Carry Siftome's disease, organism, specimen, assay, data type, and accession into a validation project. Uncertain fields remain Unknown.